FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2246363423> ?p ?o ?g. }

• W2246363423 endingPage "2308" @default.
• W2246363423 startingPage "2289" @default.
• W2246363423 abstract "Evidence suggests that the glycogen synthase kinase 3 (GSK3)-dictated nuclear exclusion and degradation of Nrf2 is pivotal in switching off the self-protective antioxidant stress response after injury. Here, we examined the mechanisms underlying this regulation in glomerular disease. In primary podocytes, doxorubicin elicited cell death and actin cytoskeleton disorganization, concomitant with overactivation of GSK3β (the predominant GSK3 isoform expressed in glomerular podocytes) and minimal Nrf2 activation. SB216763, a highly selective small molecule inhibitor of GSK3, exerted a protective effect that depended on the potentiated Nrf2 antioxidant response, marked by increased Nrf2 expression and nuclear accumulation and augmented production of the Nrf2 target heme oxygenase-1. Ectopic expression of the kinase-dead mutant of GSK3β in cultured podocytes reinforced the doxorubicin-induced Nrf2 activation and prevented podocyte injury. Conversely, a constitutively active GSK3β mutant blunted the doxorubicin-induced Nrf2 response and exacerbated podocyte injury, which could be abolished by treatment with SB216763. In murine models of doxorubicin nephropathy or nephrotoxic serum nephritis, genetic targeting of GSK3β by doxycycline-inducible podocyte-specific knockout or pharmacologic targeting by SB216763 significantly attenuated albuminuria and ameliorated histologic signs of podocyte injury, including podocytopenia, loss of podocyte markers, podocyte de novo expression of desmin, and ultrastructural lesions of podocytopathy (such as foot process effacement). This beneficial outcome was likely attributable to an enhanced Nrf2 antioxidant response in glomerular podocytes because the selective Nrf2 antagonist trigonelline abolished the proteinuria-reducing and podocyte-protective effect. Collectively, our results suggest the GSK3β-regulated Nrf2 antioxidant response as a novel therapeutic target for protecting podocytes and treating proteinuric glomerulopathies." @default.
• W2246363423 created "2016-06-24" @default.
• W2246363423 creator A5003240680 @default.
• W2246363423 creator A5026475234 @default.
• W2246363423 creator A5041867945 @default.
• W2246363423 creator A5042801057 @default.
• W2246363423 creator A5043997581 @default.
• W2246363423 creator A5046047064 @default.
• W2246363423 creator A5048518436 @default.
• W2246363423 creator A5066860889 @default.
• W2246363423 creator A5069947730 @default.
• W2246363423 creator A5070792980 @default.
• W2246363423 creator A5088548088 @default.
• W2246363423 creator A5091383290 @default.
• W2246363423 date "2015-12-08" @default.
• W2246363423 modified "2023-09-29" @default.
• W2246363423 title "Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3β Reinforces the Nrf2 Antioxidant Defense against Podocytopathy" @default.
• W2246363423 cites W1542790326 @default.
• W2246363423 cites W161240138 @default.
• W2246363423 cites W1942154378 @default.
• W2246363423 cites W1968115910 @default.
• W2246363423 cites W1973882427 @default.
• W2246363423 cites W1974016983 @default.
• W2246363423 cites W1980739328 @default.
• W2246363423 cites W1982958012 @default.
• W2246363423 cites W1999148207 @default.
• W2246363423 cites W2002721855 @default.
• W2246363423 cites W2014491132 @default.
• W2246363423 cites W2015392958 @default.
• W2246363423 cites W2015930811 @default.
• W2246363423 cites W2016038200 @default.
• W2246363423 cites W2018328223 @default.
• W2246363423 cites W2018509996 @default.
• W2246363423 cites W2025330029 @default.
• W2246363423 cites W2029742967 @default.
• W2246363423 cites W2031004071 @default.
• W2246363423 cites W2038582574 @default.
• W2246363423 cites W2038612772 @default.
• W2246363423 cites W2041992162 @default.
• W2246363423 cites W2042030608 @default.
• W2246363423 cites W2043843091 @default.
• W2246363423 cites W2046110715 @default.
• W2246363423 cites W2051659273 @default.
• W2246363423 cites W2059447116 @default.
• W2246363423 cites W2062145087 @default.
• W2246363423 cites W2062263961 @default.
• W2246363423 cites W2062934426 @default.
• W2246363423 cites W2069331145 @default.
• W2246363423 cites W2075235384 @default.
• W2246363423 cites W2081748503 @default.
• W2246363423 cites W2083308747 @default.
• W2246363423 cites W2083712509 @default.
• W2246363423 cites W2084644507 @default.
• W2246363423 cites W2084767196 @default.
• W2246363423 cites W2085574022 @default.
• W2246363423 cites W2087417855 @default.
• W2246363423 cites W2087928294 @default.
• W2246363423 cites W2091259533 @default.
• W2246363423 cites W2091945251 @default.
• W2246363423 cites W2095328109 @default.
• W2246363423 cites W2100990796 @default.
• W2246363423 cites W2110490604 @default.
• W2246363423 cites W2111554856 @default.
• W2246363423 cites W2112198271 @default.
• W2246363423 cites W2112756559 @default.
• W2246363423 cites W2112948259 @default.
• W2246363423 cites W2114546557 @default.
• W2246363423 cites W2128282944 @default.
• W2246363423 cites W2134172788 @default.
• W2246363423 cites W2140558175 @default.
• W2246363423 cites W2142737227 @default.
• W2246363423 cites W2144379934 @default.
• W2246363423 cites W2146472590 @default.
• W2246363423 cites W2149830185 @default.
• W2246363423 cites W2150448827 @default.
• W2246363423 cites W2157230648 @default.
• W2246363423 cites W2167555260 @default.
• W2246363423 cites W2168287443 @default.
• W2246363423 cites W2168517908 @default.
• W2246363423 cites W2169378494 @default.
• W2246363423 cites W2613483874 @default.
• W2246363423 cites W4249404457 @default.
• W2246363423 doi "https://doi.org/10.1681/asn.2015050565" @default.
• W2246363423 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4978041" @default.
• W2246363423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26647425" @default.
• W2246363423 hasPublicationYear "2015" @default.
• W2246363423 type Work @default.
• W2246363423 sameAs 2246363423 @default.
• W2246363423 citedByCount "59" @default.
• W2246363423 countsByYear W22463634232016 @default.
• W2246363423 countsByYear W22463634232017 @default.
• W2246363423 countsByYear W22463634232018 @default.
• W2246363423 countsByYear W22463634232019 @default.
• W2246363423 countsByYear W22463634232020 @default.
• W2246363423 countsByYear W22463634232021 @default.
• W2246363423 countsByYear W22463634232022 @default.
• W2246363423 countsByYear W22463634232023 @default.
• W2246363423 crossrefType "journal-article" @default.

• next